An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited reported a 20.90% decrease in its loss from ordinary activities after tax for the half-year ended December 31, 2024, amounting to $18,725,453. Despite the reduction in losses, the company did not declare any dividends for the current or previous financial periods, and there were no changes in controlled entities. The financial statements were reviewed by an independent auditor, who issued an unmodified opinion, reflecting stability in the company’s financial reporting.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the healthcare industry, focusing on theranostics, which combines therapy and diagnostics to develop targeted treatments for cancer and other diseases.
YTD Price Performance: 30.0%
Average Trading Volume: 10,280,767
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$60.68M
For an in-depth examination of RAD stock, go to TipRanks’ Stock Analysis page.